Introduction
============

The highest functions of the nervous system, including the cognitive capabilities of the human brain, are rooted on stereotyped and yet plastic interactions among a huge variety of neurons and glial cells, which compose the vertebrate brain. The specification of neural cells occurs with an apparently invariable precision during a protracted period of the embryonic and early postnatal life ([@B1]). In turn, the molecular information acquired by the different neuronal types is fundamental to select and restrict the establishment of brain circuit and to modify the way in which information is processed ([@B47]). All these events need to be highly coordinated in time and space with mechanisms that control how the flow of information among cells is switched off or prolonged. Therefore, understanding how the human brain is built requires the full comprehension of this diversity and of the mechanisms that finely control the formation and the posterior plasticity of neuronal circuits ([@B13]). This, in turn, is a prerequisite to identify the molecular basis of the abnormalities associates with the many disorders that affects the different structures of the brain and their function.

Proteolytical processing of membrane bound molecules acquires particular importance in the context of the brain since its function strongly depends on well-orchestrated interactions among many different cell types, including neurons and glial cells. Members of families of metalloproteinases are major effectors of these events. The meeting "Proteases at work: cues for understanding neural development and degeneration" which took place in Baeza, Spain from October 20th until October 23rd, 2014 brought together internationally recognized leaders in the field to summarize the most recent evidence demonstrating that proteases are essential for the development of the CNS, underscoring their relevance in neurodegeneration and discussing whether endogenous or pharmacological modulation of their activity represents a therapeutic tool.

*Carl Blobel* (Hospital for Special Surgery, New York, NY, USA) initiated the conference by providing an overview about proteinases belonging to the A Disintegrin and Metalloproteinase Family (ADAMs). ADAMs regulate the fate of cell surface expressed membrane proteins ([@B3]; [@B45]; **Figure [1](#F1){ref-type="fig"}**). He focused on a specific member of this family, ADAM17, and its well-established role in liberating Epidermal Growth Factor Receptor ligands from their membrane-anchor. As for the other proteolytically active members of the ADAM family, their regulation still remains a field with many open questions. In this regard, the inactive Rhomboid1 and 2 (iRhom) proteins turned out to be instrumental upstream regulators for ADAM17/EGFR signaling. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding ([@B23]). Its interaction with ADAM17 controls the cellular trafficking of the protease and its maturation in myeloid cells (**Figure [1A](#F1){ref-type="fig"}**). Disruption of both *iRhoms* genes in mice led to a phenotype comparable to the ADAM17 and EGFR-knockout mice providing clear evidence that ADAM17 is tightly controlled by both iRhoms.

![**(A)** Illustration of an A Disintegrin and Metalloproteinase (ADAM) protease, which is regulated by tetraspanin proteins (e.g., shown for ADAM10) and inactive rhomboids (shown for ADAM17). The cleavage of a membrane bound substrate protein is a hallmark of the process termed "ectodomain shedding." It regulates the function of this cell surface protein and its half-life. **(B)** Proteases play a central role in both excitatory and inhibitory synapse biology and function. ADAM10 and MMP9 may contribute to synaptic plasticity by the proteolytic processing of essential synaptic adhesion molecules, such as neuroligins and cadherins. Proteases expressed in glial cells may modulate (*in trans*) the shedding events on postsynapses as well. **(C)** The processing of amyloid precursor protein (APP) and the cellular prion protein (PrPc) is an essential element in the molecular pathogenesis of Alzheimer and Prion Disease, respectively. The reported identification of physiological (Sfrp1) and pharmacological (acitretin) modulators of their proteolytical processing adds new perspective to protease function.](fnmol-08-00013-g001){#F1}

Metalloproteinases in Brain
===========================

Closely related to ADAM17, ADAM10 exerts a number of essential functions related to the development and function of the brain. ADAM10 sheds the amyloid precursor protein (APP), the Notch receptor, and the prion protein ([@B45]). *Paul Saftig* (University Kiel, Germany) reported about a number of additional neuronal substrates of ADAM10. Conditional knockout mice with disruption of ADAM10 in the developing or adult brain revealed different and stage-dependent functions of this protease. ADAM10 controls cell fate decision events with a process that depends on the cleavage of the Notch receptor and that discriminates between neurogenesis and gliogenesis ([@B17]). In adult neurons, ADAM10 contributes to synaptogenesis mediating cleavage of adhesion proteins at the synapse (**Figure [1B](#F1){ref-type="fig"}**). Spine development, synapse plasticity, synaptic network function, memory, and learning all rely on proper cell-autonomous activity of ADAM10 ([@B30]). ADAM10 itself can be shedded by ADAM9 or ADAM15. It is thus conceivable that the glia-derived ADAM10-ectodomain could also contribute to synapse shaping *in trans*. Interestingly, trafficking of ADAM10 from the endoplasmic reticulum to its active site, the plasma-membrane, seems to be tightly controlled. Some members of the tetraspanin (TSPAN) family, including TSPAN15, associate with ADAM10 and are co-transported at the cell surface ([@B31]), where they apparently increase the life span of ADAM10 and help mediating substrate specificity (**Figure [1A](#F1){ref-type="fig"}**).

*Elena Marcello* from *Monica Di Lucaˊs* (University of Milan, Italy) laboratory also supported the idea that trafficking of ADAM10 is central to its regulation. The Synapse-Associated Protein-97 (SAP97) interacts with the cytoplasmic domain of ADAM10 ([@B20]). This binding leads to transport of the protease to the post-synaptic membrane and in an Alzheimer Disease (AD) context causes an increased α-secretase cleavage of APP. The SAP97 contact to ADAM10 is further regulated by protein kinase C phosphorylation ([@B38]). Furthermore, the adaptor protein 2 (AP2) complex controls ADAM10 endocytosis, which is triggered by long-term-potentiation in hippocampal neurons, thereby reducing its surface shedding function. Of note, this ADAM10/AP2 association seems increased in AD brains ([@B21]).

The synaptic role of ADAM10 was also the focus of *Taisuke Tomitaˊs* (University of Tokyo, Japan) presentation. The postsynaptic adhesion molecule neuroligin (NLG) binds to its presynaptic counterpart neurexin. Interestingly, NLG mutations have been linked to psychiatric disorders and mental retardation (reviewed in: [@B39]). ADAM10 cleaves NLG-1 after NMDA receptor activation. This causes an additional intra-membrane cleavage exerted by the γ-secretase complex ([@B40]). Dependent on neuronal stimulation, different members of the ADAM family may cleave different types of NLGs (**Figure [1B](#F1){ref-type="fig"}**). Therefore, ADAM proteases may be interesting targets to treat autism spectrum disorders, because, as mentioned above, NLGs have been strongly linked to these neuropsychiatric diseases ([@B39]).

The challenge for considering ADAM proteases as therapeutic targets will be the selective interference with the processing of one substrate, without considerably affecting other substrates, so to avoid undesired side effects. This is particularly important because over 65 neuronal substrates have been so far identified, as an example, for ADAM10. Some of these substrates were found using proteomic techniques in the conditioned medium of neurons derived from ADAM10 conditional knockout, as described by *Peer-Hendrik Kuhn* (Technical University Munich, Germany). This powerful approach not only validated a number of already described substrates but extended this list to previously unrecognized surface proteins involved in synapse function, axon guidance and intercellular adhesion. A similar approach previously and successfully identified new neuronal substrates for BACE-1, the β-secretase involved in APP processing ([@B18]).

Again related to synaptic function, *Leszek Kaczmarek* (Nencki Institute, Warsaw, Poland) described the pivotal importance of matrix metalloproteinase-9 (MMP-9) in the regulation of synaptic plasticity (**Figure [1B](#F1){ref-type="fig"}**), learning, and memory. MMP-9 belongs to the family of metzincins, which are enzymes secreted by neurons and glia ([@B46]) and, in contrast to ADAMs, their proteolytical activity occurs mainly in the extracellular space (**Figure [1B](#F1){ref-type="fig"}**). MMP-9 expression is tightly regulated and it is rapidly released near excitatory synapses in response to synaptic stimulation ([@B12]). MMP9 cleaves the cell adhesion molecule nectin-3 under conditions of stress ([@B43]) and its activity has been implicated in the synaptic alterations found in neuropsychiatric disorders, such as schizophrenia and autism ([@B42]).

Metalloproteinases in Development
=================================

Nervous system development depends on exquisitely coordinated cell communication, assuring that information among cells is activated where needed and switched off at or prolonged for the appropriate time. Controlled proteolysis contributes to this coordination, among others, by disrupting adhesion, modulating signaling and even regulating gene transcription, thereby influencing tissue patterning, morphogenesis and differentiation ([@B2]). *Shanthini Sockanathan* (Johns Hopkins University, Baltimore, MD, USA) illustrated this idea presenting a novel enzymatic mechanism, which controls Notch signaling, a classical example of a pathway activated by the generation of a transcriptionally active intracellular fragment ([@B27]). Indeed, the differentiation of postmitotic neurons in the spinal cord depends upon the expression of GDE2, a six *trans*-membrane protein with an extracellular glycerophosphodiester phosphordiesterase (GDPD) domain ([@B36]). GDE2 expressed by motorneurons enzymatically control the surface availability of the Notch ligand Delta1 in motor neurons, thereby promoting the differentiation of neighboring progenitors by decreasing Notch activity. GDE2 control of surface Delta occurs via a complex cascade that involves the GPI anchor cleavage of the ADAM10 repressor RECK ([@B26]).

*Avraham Yaron* (Weizmann Institute of Science, Rehovot, Israel) instead discussed the relevance of proteolytical inactivation of axon guidance signaling mediated by the Neuropilin-1 (Nrp1) receptor and its Sema3A ligand. Sema3A acts as an axonal repellent for sensory axons projecting to the spinal cord. Genetic inactivation of ADAM10/ADAM17 causes guidance errors of proprioceptive axons, because the otherwise developmentally regulated shedding of Nrp1 at the sensory growth cones does not occur. This failed shedding abnormally prolongs the growth cone repulsive response to Sema3A. Accordingly, this repulsive response is no longer observed when growth cones express a form of Nrp1 highly susceptible to cleavage, further underscoring the importance of ectodomain shedding in switching growth cone responsiveness to guidance cues ([@B34]).

Still within the concept of proper axon growth regulation but this time of mouse retinal ganglion cells (RGC), *Paola Bovolenta* (Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain) presented data supporting that Secreted Frizzled Related Proteins (Sfrps), highly diffusible secreted modulators of cell--cell communication ([@B4]), participate in mouse visual pathway development. Sfrps act by both directly signaling at the growth cone and negatively modulating ADAM-mediated proteolytical processing of other relevant cues ([@B22]). These conclusions are consistent with previous observations demonstrating, on one side, that Sfrp1 reorients chick and *Xenopus* RGC growth cones ([@B33]) and, on the other side, that Sfrp1 binds to ADAM10, down-regulating the processing of a number of its substrates, including *N*-cadherin or L1 ([@B15]), which are involved in RGC guidance.

Adhesion regulation is crucial also to establish the circuitry in the developing cortex as discussed by *Patricia Maness* (University of North Carolina at Chapel Hill, NC, USA). Alterations in the function of GABAergic basket interneurons inhibiting pyramidal cells of the prefrontal cortex are thought to be responsible for working memory deficits in schizophrenia patients. On the other hand, ADAM-mediated proteolysis of NCAM is known to participate in synaptic plasticity during learning and memory ([@B5]). Taking the two observations together *Patricia* showed that excessive shedding of NCAM is associated with a decreased GABAergic basket cell function and an impaired working memory. This is because NCAM forms a complex with EphA3, which binds to ephrinA5 and mediates ADAM10-dependent elimination of basket cell synapses during postnatal development of the prefrontal cortex. Disruption of this complex increases basket cell perisomatic synapses and inhibitory responses in the prefrontal cortex, indicating that this regulatory mechanism may limit GABAergic inhibition in the cortex, establishing an appropriate excitatory/inhibitory balance ([@B7], [@B6]).

As other organs, the brain maintains stem cell niches throughout adulthood. The mouse subependymal zone is one of these niches, in which a relatively quiescent stem population continually produces new neurons through the generation of rapidly diving, transit-amplifying progenitors ([@B29]). *Isabel Fariñas* (University of Valencia, Spain) showed that *N*-cadherin-mediated adhesion to ependymocytes contributes to the quiescence of neural stem cells in the sub-ependymal niche. More interestingly, MT5-MMP, a membrane-type metalloproteinase, sheds *N*-cadherin ectodomain in this niche, ensuring the proper activation of the stem cell population in both physiological and regenerative conditions ([@B28]), thus unveiling possible targets to stimulate neurogenesis when needed.

Following on the role of MMP, *Lieve Moons* (University Leuven, Belgium) demonstrated that two members of this family, MMP-2 and MMP-3, are required for the on-time migration of granule cells and GABAergic interneurons in the cerebellum as well as for a proper dendritic arborisation of the Purkinje cells and pyramidal neurons of the neocortex ([@B37]). Notably, genetic inactivation of these MMP causes sustained deficits in motor performance in adult mice. Comparative proteomic approaches highlighted possible underlying molecular causes ([@B44]). Furthermore, as an interesting possibility linked to visual system repair, *Lieve* also discussed the potential implications of MMP-2 and MT1-MMP as promising axon-outgrowth promoting molecules within the CNS ([@B8]; [@B16]).

Metalloproteinases in Neurodegeneration
=======================================

γ-secretase-mediated intra-membrane proteolysis is a well-defined process, which involves regulated intra-membrane proteolysis of type-1 *trans*-membrane proteins. Since APP is a major substrate of the multi-protein γ-secretase complex and its cleavage contributes to the generation of amyloidogenic Aβ peptide species, inhibition of the γ-secretase has attracted much attention as a promising therapy for AD. *Bart de Strooper* (University Leuven, VIB, Belgium) discussed the possible causes of a failed phase III clinical trial using semagacestat, a γ-secretase inhibitor. Most likely owing to the inhibition of the Notch-1 signaling pathway, patients treated with this small compound presented serious side effects, including skin cancers. Treated AD patients were also subjected to infections and paradoxically experienced further cognitive decline ([@B11]). A possible explanation for this failure might be the potential need of lowering γ-secretase enzymatic activity moderately but chronically, a kinetic that might not have been achieved with the designed treating protocol. Rather, daily oscillations of the drug levels in the CSF might have caused periods of full Notch inhibition, exacerbating the side effects. Furthermore, the potential misprocessing of other γ-secretase substrates might have also contributed to these disappointing results ([@B9]). It is thus important to design a more selective inhibition of the γ-secretase complex capable of interfering with APP processing but not with that of other substrates ([@B10]).

Related to the crucial need in Alzheimer research of developing effective therapies preventing the excessive generation of Aβ species and following the idea that Sfrp1 is one of the few soluble regulators of ADAM10, *Pilar Esteve* (Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain) showed that reduction of Sfrp1 expression shifts APP processing toward a non-amyloidogenic pathway (**Figure [1C](#F1){ref-type="fig"}**) in the adult mouse brain ([@B15]). *Nigel M. Hooper* (University of Manchester, UK) instead showed that ADAM10 sheds PrP^C^ ([@B41]), the cellular prion protein (**Figure [1C](#F1){ref-type="fig"}**), capable of binding, and mediating the toxicity of Aβ oligomers ([@B35]). This leads to the hypothesis that modulation of the shedding of PrP^C^ by ADAM10 would alter PrP^C^-Aβ oligomers' interaction and thus their neurotoxicity. Data in this direction were presented, further supporting the idea that increasing ADAM10 activity may be beneficial for AD for multiple reasons. It will increase α-secretase processing of APP that reduces Aβ and at the same time increases sAPPα generation, thought to have neuroprotective properties, including the inhibition of Aβ production ([@B25]). Furthermore, increased ADAM10-mediated shedding of PrP^C^ will buffer the toxicity of the remaining Aβ oligomers.

*Kristina Endres* (Clinic of Psychiatry and Psychotherapy, Johannes Gutenberg University, Mainz, Germany) raised several important considerations that need to be solved before pursuing ADAM10 as a therapeutic target. She underscored that it is still unclear to what extent a deficient ADAM10 catalytic activity or a reduced expression of its gene participates in AD pathogenesis. We also do not know the full network of factors regulating *ADAM10* expression in humans and whether pharmacological interference with ADAM10 enzymatic activity can be achieved in patients. More importantly, is it safe? *Kristina* reported encouraging results on both fronts with the identification of transcription factors that influence ADAM10 expression ([@B32]). She also showed that acitretin, a synthetic retinoid, safely targets ADAM10 activity since AD patients treated with this compound presented a significant increase in the CSF levels of sAPPα, providing important basis to design larger and longitudinal trials to evaluate the possible clinical benefits of this treatment ([@B14]; **Figure [1C](#F1){ref-type="fig"}**).

The importance of metalloprotesases in neurodegeneration is not limited to AD or autism spectrum disorders and the case of another severely debilitating illness was illustrated. *Elena Cattaneo* (University of Milan, Italy) reported the power of combining evolutionary and developmental approaches to study disease-genes such as that encoding the ancestral protein Huntingtin. Expansion over 36 residues of a polymorphic tri-nucleotide CAG repeat, translated into polyglutamine, causes Hungtington Disease (HD), a genetically dominant and fatal neurodegeneration ([@B48]). Huntingtin exerts a number of activities in the adult brain, such as promoting the transcription of the neurotrophin BDNF ([@B49]), critical for the survival and activity of the neurons that degenerate in HD. Unexpectedly, huntingtin has also evolved to acquire the unique regulatory activity of controlling neural adhesion by inhibiting ADAM10-mediated processing of *N*-cadherin ([@B19]). Besides developmental implications, these observations suggest that ADAM10 might be explored as a new target in the treatment of HD ([@B19]).

Conclusion and Perspectives
===========================

Altogether the findings clearly highlighted that metalloproteases are instrumental for proper development of the CNS and of the embryo in general. Most of the basic developmental processes in the CNS involve some type of metalloproteases, which in general exert a beneficial role: they activate pathways that promote neurogenesis, regulate the migration of neurons or the correct growth of axons to their final destinations. Most of the evidence so far indicates that metalloproteases regulate the latter process by degrading axon guidance cues, such as netrin and its receptor DCC or Eph-ephrin molecules ([@B2]). Nevertheless, the recent identification of metalloprotease-enriched "invadosomes" in the growth cones of all the neurons so far tested ([@B37]), suggests that metalloproteases might tune other class of molecules such as those involved in focal adhesion. Although not touched upon in this workshop, metalloproteases also cooperate for proper axon myelination and the formation of the extensive vasculature of the brain ([@B46]). Other developmental events are also likely to require proteases' function. For example, brain colonization by microglial cell is a poorly explored phenomenon that resemble metastatic invasion, a process in which metalloproteases have a well-established role ([@B24]). Furthermore, microglia cell and astrocytes participate in the regulation of synaptic plasticity and it is quite likely that part of their roles might be mediated by secreted or membrane bound proteases, acting in *cis* or even in *trans*, as mentioned.

Unfortunately, metalloproteases are not always associated to positive events, as their activation or over-activation is often detrimental. As discussed in the workshop, neurodegenerative disorders are a primary example of harmful effect together with metastatic disorders. The role of metalloproteases in these pathologies has been the focus of several laboratories for many years. More recently, general pathological processes such as neuroinflammation have emerged as metalloprotease-regulated events, broadening the implication of these molecules. Thus, it is apparent that we are just observing the tip of the iceberg as we still know little of the physiological relevance of metalloproteases in the brain. Full understanding of their function might unravel how the same protease can have a double edge and might give us some hints on how to turn metalloproteases' detrimental side into a beneficial activity. Reaching this degree of comprehension requires answering a large list of questions, and we would like to point out some of them, which perhaps represent the most obvious ones (**Table [1](#T1){ref-type="table"}**).

###### 

Main open questions in the field of neurobiology linked to protease activities.

  ------------------------------------------------------------------------------------------------------------------------------
  What is the portfolio of substrates of a given protease under different conditions?
  How is substrate specificity established and modulated?
  How does a protease network in a given cell work? How many proteases can use the same substrate and in which sequence?
  How can a protease activity be physiologically modulated? What are the protein or lipid factors affecting protease function?
  What are the factors affecting protease function in specific tissues or specific developmental processes?
  Which signaling processes control intra- and extracellular active proteases?
  How do proteases protect themselves from proteolytic activity?
  Are proteases suited as therapeutic targets to modulate their activity in the CNS?
  Can proteolytical activity be exploited to favor CNS regeneration or neurological diseases?
  ------------------------------------------------------------------------------------------------------------------------------

Likely, more protease activities needs to be identified. The number of substrates each protease can cleave seems to be large. What is the spectrum of substrates used by a specific protease under a given physiological condition? Is there substrate specificity and how is it established? Do proteases compete for the same substrate and how coordination among different proteases is achieved? How is their expression regulated? The physiological modulators of protease activity are also largely unknown: how many are there? Are they specific, likely contributing to define protease/substrate interaction and how do they influence developmental decisions and tissue homeostasis? What is the contribution of ADAMs and MMPs to excitatory and inhibitory synapse formation and homeostasis? How far can proteases act *in trans* in the CNS?

Answering all these questions will certainly lead to a better understanding of metalloproteinase biology but it will require the development of new experimental tools and animal models. For example, there is the need of more sophisticated proteomic approaches, which together with the generation of specific antibodies will be instrumental to fully understand the spectrum of peptides generated by ectodomain shedding or by other types of protease activities. The generation of knock-in mouse mutants with defined mutations in different protease domains should help exploring their precise function and also model human diseases. Furthermore, the recent introduction of new genome editing techniques might be instrumental to tag metalloprotease or their substrates, which could help following proteolytical events and the final destiny of the end products. Most of the work in metalloproteases has been performed in cell lines or mammalian models, but other experimental species, such as the zebrafish, might become handy, especially to tackle metalloprotease implication in developmental events *in vivo*.

When considering the devastating frequency of developmental (autism spectrum disorders) and neurodegenerative (AD and Prion Disease) disorders so far known to be associated to the impaired activity of metalloropeases, it is evident that improving our understanding of metalloprotease biology may have important social benefits, in addition to a scientific relevance. As mentioned above, there is already a considerable effort in exploiting metalloproteases for therapeutics purposes. The task is huge as a protease-targeted therapy will need careful evaluation and it is expected to work only in a tight therapeutic window. Unwanted side effects explained by the modulation of other protease-substrate complexes have to be taken into consideration. Nevertheless, there are considerable expectations that we all hope to foster in the years to come.
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